Q & A With the Author (Peschken)

Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic Christine A. Peschken DOI: https://doi.org/10.3899/jrheum.200395 As the coronavirus disease 2019 (COVID-19; the disease caused by SARS-CoV-2) pandemic took hold in North America, rheumatology clinics across the continent were inundated with phone calls from patients with systemic lupus erythematosus (SLE) who were understandably fearful of COVID-19. One of the most common questions from patients was whether they should stop taking their medications.